|
|
News Breaks | | | | March 5, 2013 | | 08:00 EDT |  | VVUS, VVUS, UTHR, UTHR, TRGT, TRGT, ONCY, ONCY, OCR, OCR, NKTR, NKTR, CNDO, CNDO, BRKR, BRKR, ARRY, ARRY, AGN, AGN | Cowen to host a conference
33rd Annual Health Care Conference is being held in Boston on March 4-6 with webcasted company presentations to begin on March 5 at 8 am; not all company presentations may be webcasted. Webcast Link | |
|
News For AGN;ARRY;BRKR;CNDO;NKTR;OCR;ONCY;TRGT;UTHR;VVUS From The Last 14 Days Check below for free stories on AGN;ARRY;BRKR;CNDO;NKTR;OCR;ONCY;TRGT;UTHR;VVUS the last two weeks. |
|
|
| June 18, 2013 | | 09:04 EDT | | AGN | Wells Faro to host a conference
2013 Healthcare Conference is being held in Boston on June 18-19 with webcasted company presentations to begin at 8:15 am; not all company presentations may be webcasted. Webcast Link | | | 08:36 EDT |  | AGN | Elan shares could be worh $19 in a buyout, says Jefferies
Jefferies raised its price target for shares of Elan (ELN) to $19 from $14, reflecting what it sees as the value of the company in a takeout scenario. The firm says Elan management suggested they would be open to sale in the $15-$20 per share range. Jefferies believes a high taxpaying suitor could pay the upper end of that range, and lists Allergan (AGN), Regeneron (REGN), Vertex (VRTX), Alexion (ALXN), Zoetis (ZTS), Mylan (MYL) and Perrigo (PRGO) as potential acquirers for Elan. Shares of Elan are up 13c to $13.62 in pre-market trading after Royalty Pharma announced that its buyout proposal for the company has expired. | | | 07:28 EDT | | AGN | Wells Faro to host a conference
 Subscribe for More Information | | | June 17, 2013 | | 09:02 EDT | | OCR | Omnicare, Walgreen's should not see margin falloff, says UBS
Subscribe for More Information | | | 08:01 EDT |  | ARRY | Array BioPharma announces positive interim results from tiral of ARRY-520
Subscribe for More Information | | | 07:28 EDT | | ARRY | Cambridge Healthtech Institute to host a conference
Subscribe for More Information | | | 07:11 EDT | | VVUS | VIVUS urges stockholders to vote on the GOLD proxy card
VIVUS mailed a letter to stockholders advising them to protect the value of their investment in VIVUS by voting the GOLD proxy card. The letter stated "VIVUS stockholders face an important decision at the upcoming 2013 VIVUS Annual Meeting of Stockholders. Your board and management team have made substantial progress in laying the foundation for Qsymia, and now we are poised to drive future sales by providing broad access to the millions of patients whose lives would benefit from this important therapy. While much progress has already been made, careful and timely execution of the next phase of our retail commercialization plan will be critical to the success of VIVUS. This phase of our retail commercialization plan, after REMS modification, requires a major pharmaceutical company to reach the primary care physicians. As such, we are in discussions with large pharmaceutical companies to explore opportunities as to how we may work together to maximize sales of Qsymia. We strongly believe that electing First Manhattan nominees at the Annual Meeting will jeopardize the progress we are making, and will throw VIVUS into turmoil. At this critical juncture in the company's history, FMC, which owns less than 10% of the company's stock, is trying to seize control of 100% of the VIVUS Board and your company. We strongly urge you not to jeopardize the important progress your Board and management team are making and risk your investment." | | | 06:07 EDT | | ARRY | Array BioPharma pullback a buying opportunity, says Piper Jaffray
Subscribe for More Information | | | June 11, 2013 | | 13:09 EDT | | AGN | Allergan has a conference call hosted by BMO Capital
Subscribe for More Information | | | 08:05 EDT | | CNDO | Coronado Biosciences weakness creates buying opportunity, says Oppenheimer
Subscribe for More Information | | | | June 7, 2013 | | 07:04 EDT | | VVUS | VIVUS drug Qsymia cited in The Journal of Diabetes and Its Complications
Subscribe for More Information | | | June 6, 2013 | | 06:40 EDT | | OCR | Omnicare cold be a takeout candidate, says Credit Suisse
Credit Suisse said Omnicare's Change in Control Plan leads it to speculate that there is outside interest in the company. The analyst believes Omnicare's improving operations in its Long-term Care Group and growing Specialty business makes it a potential target. Shares are Outperform rated with a $52 price target, up from $50. | | | June 4, 2013 | | 11:17 EDT | | VVUS | First Manhattan mails proxy statement, sends letter to Vivus shareholders
Subscribe for More Information | | | 07:11 EDT | | BRKR | Bruker, 3M sign exclusive patent license agreement
Bruker (BRKR) announced that it has signed an exclusive patent license agreement with 3M Company (MMM), which allows Bruker to include 3M patented innovations relating to matrix-assisted laser desorption ionization mass spectrometry imaging. The technology enables researchers to more easily study formalin-fixed, paraffin-embedded tissue for life-science research and drug development, the company said. | |
|
|
|
|
|
|
